The study is a single arm, prospective study of the safety and effectiveness of the Valencia Technologies eCoin System to stimulate the tibial nerve for the treatment of patients with refractory urgency urinary incontinence.
This trial is a single arm, prospective study of the safety and effectiveness of eCoin tibial nerve stimulation in 25 subjects with refractory overactive bladder as defined by the American Urological Association.. The eCoin neuromodulation device will be implanted subcutaneously in the right or left leg of patients with urgency urinary incontinence. After a 4 week implant healing period, subjects will have their devices activated (turned ON). After 3 months of device therapy (occurring 4 months post-implant), the primary endpoint will be assessed. It is anticipated that subjects will reach the full therapeutic effect at approximately 3 months of therapy. Subjects will be followed for an additional 9 months to assess the safety of maintenance stimulation therapy with fewer sessions occurring during this time interval.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
46
Patients are implanted with active implantable device called eCoin. eCoin is turned ON in order to deliver neuromodulation therapy.
The Clark Center for Urogynecology
Newport Beach, California, United States
UnityPoint Clinic
Waterloo, Iowa, United States
Alliance Urology Specialists
Greensboro, North Carolina, United States
The Institute for Female Pelvic Medicine & Reconstructive Surgery (FPM Institute)
Allentown, Pennsylvania, United States
Incontinent Episodes
The change in number of incontinence episodes from baseline to three months post-activation.
Time frame: Baseline to three months post-activation.
System and Procedure Related AEs
Number of System and Procedure Related Adverse Events from implantation to one month post-implantation.
Time frame: Implantation to one month post-implantation.
MAEs
Number of all Major Adverse Events from baseline to 3 months post-activation.
Time frame: Baseline to 3 months post-activation.
Percentage of Responders
Percentage of Responders, defined as participants who experienced a 50% or greater reduction in UUI after 3 months of treatment
Time frame: 3 months after activation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Urology Associates
Christchurch, New Zealand
Roundhay Medical Centre
Nelson, New Zealand
Tauranga Urology Research Ltd
Tauranga, New Zealand